Abstract graphic of an eye
Investor Relations

Press Release

Harvard Bioscience Announces First Quarter 2021 Financial Results

May 6, 2021

Sales effectiveness, pre-clinical product demand and disciplined cost management result in improved revenues and margins

  • Revenue up 14% as sales momentum from Q4’20 continues
  • Pre-clinical product revenue up 24%
  • Operating margin significantly improves year-over-year on GAAP and adjusted basis

HOLLISTON, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the three months ended March 31, 2021.

Jim Green, Chairman and CEO said, “Our first quarter revenue reflects continuation of the sales momentum we saw in the fourth quarter last year, driven by focus on sales effectiveness, demand for our pre-clinical products and recovering academic lab sales. Q1 pre-clinical product revenue grew 24%, with strong sales of our new inhalation product. Revenue growth coupled with cost management and reduction in sales of lower value products delivered strong operating margin expansion, all while significantly bringing down our leverage ratio.”  

Green concluded, “With our strong momentum and improving confidence in our business, our outlook for 2021 continues to improve. We are now expecting revenue growth of 10% to 14% for fiscal 2021 compared to 2020 and expect adjusted operating margin expansion to the mid-to-upper teens. This growth allows for disciplined reinvestment in growth initiatives to stay on track to creating the growth oriented, profitable platform we envisioned.”


  Quarterly Financial Results Summary Q1'21 Q1'20  
  Revenue $ 27.0   million $ 23.8   million  
  Operating Loss (GAAP) $ (0.2 ) million $ (3.3 ) million  
  Adjusted Operating Income $ 3.2   million $ 0.5   million  
  Operating Margin (GAAP)   (0.9 ) %     (13.8 ) %  
  Adjusted Operating Margin   12.0   %     2.0   %  
  Loss Per Share (GAAP) $ (0.02 )       $ (0.12 )      
  Adjusted Diluted Earnings (Loss) Per Share $ 0.05       $ (0.01 )      
  Net Debt* $ 39.1   million $ 44.3   million  
  * Debt outstanding less cash and cash equivalents            

Please refer to the exhibits below for a reconciliation of certain non-GAAP to GAAP financial measures, including operating income, net income and loss, and diluted earnings per share. Please see “Use of Non-GAAP Financial Information” for additional information regarding our use of such adjusted financial information.

Webcast and Conference Call Details

Harvard Bioscience will be hosting a conference call and webcast today at 8:00 a.m. Eastern Time. You can access the live conference call by dialing the following phone numbers: toll-free 1 (877) 303-7611 or international 1 (970) 315-0445 and referencing the conference ID# 5876756.

The conference call will be simultaneously webcast and can be accessed through the Harvard Bioscience website. A slide presentation that will be referenced during the webcast will be posted to our Investor Relations website shortly before the webcast begins. To listen to the webcast, log on to the webcast at: http://investor.harvardbioscience.com/ and click on the Earnings Call icon.

Use of Non-GAAP Financial Information

In this press release, we have included non-GAAP financial information including adjusted operating income, adjusted net income, and adjusted diluted earnings per share. We believe that this non-GAAP financial information provides investors with an enhanced understanding of the underlying operations of the business. For the periods presented, these non-GAAP financial measures have excluded certain expenses and income primarily resulting from purchase accounting or events that we do not believe are related to the underlying operations of the business such as amortization of intangibles related to acquisitions, costs related to acquisition, disposition and integration initiatives, impairment charges, severance, restructuring and other business transformation expenses, and stock-based compensation expense. They also exclude the tax impact of the reconciling items. This non-GAAP financial information approximates information used by our management to internally evaluate the operating results of the Company. Tabular reconciliations of our adjusted operating income, adjusted net income (loss), and adjusted earnings (loss) per diluted share are included as exhibits below in this press release.

The non-GAAP financial information provided in this press release should be considered in addition to, not as a substitute for, the financial information provided and presented in accordance with GAAP and may be different than other companies’ non-GAAP financial information.

About Harvard Bioscience

Harvard Bioscience is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Our customers range from renowned academic institutions and government laboratories, to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.

For more information, please visit our website at www.harvardbioscience.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. You can identify these statements by our use of such words as "will," "guidance," "objectives," "optimistic," "potential," "future," "expects," "plans," "estimates," "continue," "drive," "strategy," "potential," "potentially," "growth," "long-term," "projects," "projected," "intends," "believes," "goals," "sees," "seek," "develop" "possible" "new," "emerging," "opportunity," "pursue" and similar expressions that do not relate to historical matters. Forward-looking statements in this press release or that may be made during our conference call may include, but are not limited to, statements or inferences about the Company's or management's beliefs or expectations, the Company's anticipated future revenues and earnings, the strength of the Company's market position and business model, industry outlook, the impact of the COVID-19 pandemic on the Company’s business, the Company's business strategy, the positioning of the Company for growth, the market demand and opportunity for the Company's current products, or products it is developing or intends to develop, and the Company's plans, objectives and intentions that are not historical facts. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Investors should note that many factors, as more fully described under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020, and in our other filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein may cause the Company's actual results to differ materially from those in the forward-looking statements. The forward-looking statements in this press release are qualified by these risk factors. The Company's results may also be affected by factors of which the Company is not currently aware. The Company may not update these forward-looking statements, even though its situation may change in the future, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.

For investor inquiries, please contact Michael A. Rossi, Chief Financial Officer at (508) 893-8999.


            Exhibit 1    
Consolidated Statements of Operations  
(unaudited, in thousands, except per share data)  
    Three Months Ended    
     March 31, 2021    March 31, 2020    
Revenues $ 26,989     $ 23,771      
Cost of revenues   11,558       10,789      
  Gross profit   15,431       12,982      
Operating expenses:              
  Sales and marketing expenses   5,386       5,579      
  General and administrative expenses   6,333       6,759      
  Research and development expenses   2,487       2,490      
  Amortization of intangible assets   1,464       1,427      
Total operating expenses   15,670       16,255      
Operating loss   (239 )     (3,273 )    
Other expense:              
  Interest expense   (411 )     (1,299 )    
  Other (expense) income, net   (34 )     111      
Total other expense   (445 )     (1,188 )    
Loss before income taxes   (684 )     (4,461 )    
Income tax (benefit) expense   (15 )     55      
Net loss $ (669 )   $ (4,516 )    
Loss per common share:              
  Basic and diluted $ (0.02 )   $ (0.12 )    
Weighted-average common shares:              
  Basic and diluted   39,787       38,329      


            Exhibit 2      
Condensed Consolidated Balance Sheets    
(unaudited, in thousands)    
  March 31, 2021   December 31, 2020    
Cash and cash equivalents $ 5,815     $ 8,317      
Accounts receivables   17,074       17,766      
Inventories   22,676       22,262      
Other current assets   3,658       3,355      
Total current assets   49,223       51,700      
Property, plant and equipment   3,699       3,960      
Goodwill and other intangibles   90,107       91,741      
Other long-term assets   8,220       8,853      
Total assets $ 151,249     $ 156,254      
Liabilities and Stockholders' Equity                  
Current portion, long-term debt $ 1,970     $ 1,721      
Other current liabilities   18,748       19,332      
Total current liabilities   20,718       21,053      
Long-term debt   41,601       46,286      
Other long-term liabilities   11,815       12,234      
Stockholders’ equity   77,115       76,681      
Total liabilities and stockholders’ equity $ 151,249     $ 156,254      


          Exhibit 3    
Condensed Consolidated Statements of Cash Flows  
(unaudited, in thousands)  
    Three Months Ended    
  March 31, 2021   March 31, 2020    
Cash flows from operating activities:              
Net loss $ (669 )   $ (4,516 )    
Adjustments to operating cash flows   2,894       2,640      
Changes in operating assets and liabilities   (1,188 )     4,747      
Net cash provided by operating activities   1,037       2,871      
Cash flows from investing activities:              
Additions to property, plant and equipment   (151 )     (241 )    
Addition to intangible assets   (150 )     -      
Net cash used in investing activities   (301 )     (241 )    
Cash flows from financing activities:              
Repayments of debt   (4,500 )     (4,829 )    
Payments of debt issuance costs   (101 )     -      
Proceeds from exercise of stock options   1,924       -      
Taxes paid for issuance of stock   (464 )     (242 )    
Net cash used in financing activities   (3,141 )     (5,071 )    
Effect of exchange rate changes on cash   (97 )     (12 )    
Decrease in cash and cash equivalents   (2,502 )     (2,453 )    
Cash and cash equivalents at the beginning of period   8,317       8,335      
Cash and cash equivalents at the end of period $ 5,815     $ 5,882      


          Exhibit 4    
Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)    
(in thousands, except per share data)    
  Three Months Ended    
  March 31, 2021   March 31, 2020    
GAAP operating loss $ (239 )   $ (3,273 )    
Stock-based compensation expense   968       793      
Severance, restructuring and transformation costs   985       1,471      
Acquired assets amortization and impairments   1,513       1,484      
Adjusted operating income $ 3,227     $ 475      
GAAP operating margin   -0.9 %     -13.8 %    
Adjusted operating margin   12.0 %     2.0 %    
GAAP net loss $ (669 )   $ (4,516 )    
Stock-based compensation expense   968       793      
Severance, restructuring and transformation costs   985       1,471      
Acquired assets amortization and impairments   1,513       1,484      
Income tax (expense) benefit (A)   (744 )     287      
Adjusted net income (loss) $ 2,053     $ (481 )    
GAAP loss per diluted share $ (0.02 )   $ (0.12 )    
Adjusted items after tax per share assuming dilution   0.07       0.11      
Adjusted earnings (loss) per diluted share $ 0.05     $ (0.01 )    
Weighted average diluted common shares:              
GAAP   39,787       38,329      
Adjusted   42,109       38,329      
(A)    Income taxes includes the tax effect of the adjustments to GAAP results.